Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer

Akira Miyajima, Eiji Kikuchi, Takeo Kosaka, Mototsugu Oya

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


The potential for angiotensin II (AII) to promote tumor growth has been suspected based on its known hormonal actions and its vasoconstrictor effect. It has been suggested that angiotensin-converting enzyme (ACE) inhibitors may offer protection against cancer and may prevent carcinogenesis. Several studies report that AII can induce neovascularization in experimental systems by way of the AII type 1 receptor (AT1R). AT1R is also frequently expressed in such human tumors as skin cancer, renal cell carcinoma, and breast cancer. A growing number of recent studies focusing on treatment with an AT1R antagonist have demonstrated that angiotensin receptor blockade (ARB) appears to inhibit not only the growth of cancer cells but also tumor angiogenesis. We describe here the effects of AT1R blockade that implicate tumor angiogenesis in urogenital cancer since ARB may be an alternative modality for anti-cancer treatment.

Original languageEnglish
Pages (from-to)75-78
Number of pages4
JournalReviews on Recent Clinical Trials
Issue number2
Publication statusPublished - 2009 Jul 30


  • Angiogenesis
  • Angiotensin
  • Bladder
  • Kidney
  • Prostate
  • Receptor

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in urogenital cancer'. Together they form a unique fingerprint.

Cite this